UCL is today launching the UCL Technology Fund to invest £50 million in commercialising its world-leading research emerging over the next five years.
A pharmacist for 26 years with a PhD in Health Informatics, Bridget Coleman took on a new challenge when she signed up for the KEA (Knowledge Exchange Associate) programme at UCL Advances. Bridget works with the anticoagulation and stroke prevention services at the Whittington Hospital in London, looking at treatments for conditions caused by blood clots.
A long-awaited breakthrough occurred in February 2013, when UCL Business (UCLB) signed a licensing agreement with US biotechnology firm Biomarin to develop a new Factor VIII gene therapy programme. The agreement came after a 2011 trial in which the Royal Free London NHS Foundation Trust reported that six people with haemophilia B saw a reduction in symptoms after gene therapy on liver cells. This breakthrough might pave the way for potentially curative life-saving treatment to become widely available.